In Re Glumetza Antitrust Litigation
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
In re No. C 19-05822 WHA GLUMETZA ANTITRUST No. C 19-05831 WHA LITIGATION. No. C 19-06138 WHA No. C 19-06156 WHA No. C 19-06839 WHA This Document Relates to: No. C 19-07843 WHA
No. C 19-05822 WHA (Consolidated) No. C 19-06138 WHA No. C 19-06839 WHA ORDER RE FINAL APPROVAL OF
CLASS SETTLEMENTS AND
MOTION FOR ATTORNEY’S FEES
15 16 INTRODUCTION In this antitrust action, defendant brand and generic manufacturers of a type 2 diabetes drug engaged in a reverse-payment scheme and agreed not to compete with each other by delaying the introduction of a generic version of the drug for several years. On the precipice of trial, the direct-purchaser class reached settlement agreements with all defendants. To the extent stated, the motion for final approval of the settlements is GRANTED. Class counsel’s motion for attorney’s fees and…